www.fdanews.com/articles/86818-provectus-moves-forward-with-metastatic-melanoma-trial
PROVECTUS MOVES FORWARD WITH METASTATIC MELANOMA TRIAL
May 15, 2006
Provectus has announced that a second group of subjects has been treated in the company's Phase I clinical trial of PV-10 (Provecta) for ablation of metastatic melanoma, an aggressive and often fatal form of skin cancer. Treatment with PV-10 was well tolerated by all
subjects, with no evidence of systemic or serious local side effects.
The
study consists of 20 subjects, and is being conducted at the Sydney Melanoma Unit
and the Newcastle Melanoma Unit, both located in New South Wales, Australia. Each
subject enrolled in the study has one or more tumors treated with a single injection
of PV-10 and the local response to the treatment is then observed for a period
of 12 to 24 weeks.